Who Paid My Doc
Candin
Biological Immunotherapy
NDC 59584-138-01
General payments
$24,863
Research payments
$4,344,164
Through program year 2025, $24,863 in general payments and $4,344,164 in research payments were reported against Candin (Immunotherapy).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $24,863 | 5 |
| 2025 | Research | $976,202 | 23 |
| 2024 | Research | $3,313,139 | 24 |
| 2023 | Research | $21,100 | 1 |
| 2021 | Research | $2,688 | 1 |
| 2019 | Research | $31,035 | 1 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
5 general · 50 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.